Anti-complement effects of two anti-inflammatory agents. Niflumic and flufenamic acids.
D000814:Aniline Compounds / Q000494:pharmacology; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D000906:Antibodies / Q000302:isolation & purification; D002021:Buffers; D002118:Calcium / Q000037:antagonists & inhibitors; D002614:Chelating Agents / Q000494:pharmacology; D003169:Complement Inactivator Proteins; D003165:Complement System Proteins / Q000302:isolation & purification; D003956:Dialysis; D004355:Drug Stability; D004492:Edetic Acid / Q000494:pharmacology; D004912:Erythrocytes / Q000276:immunology; D005439:Flufenamic Acid / Q000494:pharmacology*; D006168:Guinea Pigs; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D007700:Kinetics; D008274:Magnesium / Q000037:antagonists & inhibitors; D009539:Nicotinic Acids / Q000494:pharmacology*; D010695:Phlorhizin / Q000494:pharmacology; D011817:Rabbits / Q000276:immunology; D012756:Sheep / Q000276:immunology; D013329:Structure-Activity Relationship; D013997:Time Factors; D062367:ortho-Aminobenzoates / Q000494:pharmacology*
D000814:Aniline Compounds; D000893:Anti-Inflammatory Agents; D000906:Antibodies; D002021:Buffers; D002614:Chelating Agents; D003169:Complement Inactivator Proteins; D009539:Nicotinic Acids; D062367:ortho-Aminobenzoates; D005439:Flufenamic Acid; D003165:Complement System Proteins; D004492:Edetic Acid; D010695:Phlorhizin; D008274:Magnesium; D002118:Calcium